OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

Roginolisib

aka IOA-244

Roginolisib is an oral pi3k inhibitor from iOnctura, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.